Stock Events

Stock Events

Ignyte Acquisition 

$0.02
4
+$0+0% Thursday 20:00

Statistics

Day High
0.07
Day Low
0.05
52W High
0.26
52W Low
0
Volume
1,931
Avg. Volume
3,276
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26FebExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2024
Q2 2024
Q3 2024
Q4 2024
-0.46
-0.28
-0.1
0.08
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PKBO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a leader in mRNA technology, directly competing with Peak Bio's focus on innovative biotechnologies for therapeutics.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes in the same space as Peak Bio, especially in the development of mRNA-based vaccines and therapies.
Pfizer
PFE
Mkt Cap140.15B
Pfizer collaborates with BioNTech on mRNA vaccines, positioning it as a competitor in the biotech space relevant to Peak Bio's interests.
Novavax
NVAX
Mkt Cap1.36B
Novavax is involved in the development of vaccines for infectious diseases, competing with Peak Bio's therapeutic and vaccine development efforts.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is focused on gene editing, a cutting-edge biotechnology that could compete with Peak Bio's innovative therapeutic approaches.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another company working on CRISPR technology, directly competing with Peak Bio in the gene editing and therapy space.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing sector, making it a competitor to Peak Bio in the pursuit of novel genetic therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is engaged in creating transformative medicines for serious diseases, potentially competing with Peak Bio's therapeutic developments.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovative biologic medicines, competing with Peak Bio in the biopharmaceutical field.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, competing with Peak Bio in the realm of RNA-based therapies.

About

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
Show more...
CEO
Employees
6
Country
US

Listings

0 Comments

Share your thoughts

FAQ

What is Ignyte Acquisition stock price today?▼
The current price of PKBO is $0.02 USD — it has increased by +0% in the past 24 hours. Watch Ignyte Acquisition stock price performance more closely on the chart.
What is Ignyte Acquisition stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ignyte Acquisition stocks are traded under the ticker PKBO.
How many employees does Ignyte Acquisition have?▼
As of April 05, 2026, the company has 6 employees.
In which sector is Ignyte Acquisition located?▼
Ignyte Acquisition operates in the Professional, Scientific, and Technical Services sector.
When did Ignyte Acquisition complete a stock split?▼
Ignyte Acquisition has not had any recent stock splits.